Drug Profile
BMS 986141
Alternative Names: BMS-986141; UDM-003183Latest Information Update: 15 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Institute for Research in Immunology and Cancer - Commercialization of Research
- Developer Bristol-Myers Squibb
- Class Antithrombotics; Benzamides; Benzofurans; Ethers; Imidazoles; Small molecules; Thiadiazoles; Thiazoles
- Mechanism of Action PAR-4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Thrombosis
Most Recent Events
- 25 Mar 2022 Phase-II clinical trials in Thrombosis in United Kingdom (PO) (NCT05093790)
- 26 Oct 2021 Bristol-Myers Squibb plans a phase IIa trial for Coronary artery disease (Combination therapy) in the United Kingdom, in October 2021 (NCT05093790)
- 01 Oct 2021 Chemical structure information added